Does Topical Steroid Treatment Impair the Adrenal Function?

Low Dose (1mcg) ACTH Stimulation Test for Assessment of the Hypothalamo-Pituitary- Adrenal Axis in Patients Treated With Topical Corticosteroids

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00476489

Enrollment

Registered

2007-05-22

Start date

2007-05-31

Completion date

Unknown

Last updated

2007-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothalamus-Pituitary-Adrenal Axis Assessement, Topical Steroid Therapy in Chronic Skin Diseases

Keywords

secondary adrenal insuffiency, hypothalamus-pituitary-adrenal axis impairement, topical steroids

Brief summary

The purpose of this study is to determine if topical steroids treatment for different skin diseases suppress the adrenal cortisol production.

Detailed description

Adrenocortical suppression is a potential complication of systemic corticosteroid treatement but also of non systemic therapy like topical therapy. The normalcy of hypothalamic-pituitary-adrenal axis ( HPA axis) of patients with chronic skin diseases like atopic dermatitis, pemphigus or psoriasis which are treated with topical steroids, will be assessed with the low dose (1mcg) adrenocortocotropin ( ACTH) stimulation test. During this test serum cortisol levels are measured before, 30 and 60 mn after intravenous administration of 1mcg of ACTH (synacthen).The results will be compared with age and sex matched subjects with normal HPA axis as assessed by low dose ACTH stimulation test.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients receiving daily topical steroids for at least two weeks on 10% or more of body surface.

Exclusion criteria

* patients treated with any form of corticosteroids except topical steroids. * patients with known pituitary disease * pregnant patients

Countries

Israel

Contacts

Primary ContactAvraham Ishay, MD

ishay_av@clalit.org.il972-4-6495556

Backup ContactRafael Luboshitzky, MD

r_luboshitzky@clalit.org.il

Outcome results